Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models

Shiteng Suo1,2†, Yan Yin1†, Xiaochuan Geng1†, Dandan Zhang1, Jia Hua1†, Fang Cheng1, Jie Chen1†, Zhiguo Zhuang1, Mengqiu Cao1 and Jianrong Xu1

Abstract

Background: To investigate the performance of diffusion-weighted (DW) MRI with mono-, bi- and stretched-exponential models in predicting pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) for breast cancer, and further outline a predictive model of pCR combining DW MRI parameters, contrast-enhanced (CE) MRI findings, and/or clinical-pathologic variables.

Methods: In this retrospective study, 144 women who underwent NACT and subsequently received surgery for invasive breast cancer were included. Breast MRI including multi-b-value DW imaging was performed before (pretreatment), after two cycles (mid-treatment), and after all four cycles (post-treatment) of NACT. Quantitative DW imaging parameters were computed according to the mono-exponential (apparent diffusion coefficient [ADC]), bi-exponential (pseudodiffusion coefficient and perfusion fraction), and stretched-exponential (distributed diffusion coefficient and intravoxel heterogeneity index) models. Tumor size and relative enhancement ratio of the tumor were measured on contrast-enhanced MRI at each time point. Pre-treatment parameters and changes in parameters at mid- and post-treatment relative to baseline were compared between pCR and non-pCR groups. Receiver operating characteristic analysis and multivariate regression analysis were performed.

Results: Of the 144 patients, 54 (37.5%) achieved pCR after NACT. Overall, among all DW and CE MRI measures, flow-insensitive ADC change (ΔADC200,1000) at mid-treatment showed the highest diagnostic performance for predicting pCR, with an area under the receiver operating characteristic curve (AUC) of 0.831 (95% confidence interval [CI]: 0.747, 0.915; P < 0.001). The model combining pre-treatment estrogen receptor and human epidermal growth factor receptor 2 statuses and mid-treatment ΔADC200,1000 improved the AUC to 0.905 (95% CI: 0.843, 0.966; P < 0.001).

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Neoadjuvant chemotherapy (NACT) has been established as one of the standard therapies for locally advanced (inoperable) or large (operable) breast cancers [1, 2]. NACT enables tumor downstaging, thus rendering inoperable tumors operable or even allowing breast-conserving surgeries. Moreover, NACT makes it possible to monitor the tumor response in vivo during treatment when compared with adjuvant chemotherapy. In particular, a pathologic complete response (pCR) after NACT has been associated with lower distant recurrence and better disease-free survival [3]. Therefore, prediction of response to NACT is crucial to optimizing treatment plan and improving individual patient-tailored management.

Noninvasive MRI plays an important role in the assessment of treatment response to NACT in breast cancer patients [4, 5]. Contrast-enhanced (CE) MRI is known as the standard imaging modality for treatment monitoring due to its high resolution and high sensitivity in breast tissues. Currently, the most widely used metric for measuring tumor change during NACT is morphologic size on CE MRI. However, changes in lesion size on breast MRI has been found to lag behind microstructural and functional alterations [6, 7].

Diffusion-weighted (DW) MRI, a functional imaging modality which reflects Brownian motion of water molecules in biologic tissues, has been extensively explored for the potential to predict therapy outcome for responders. The apparent diffusion coefficient (ADC) measured at DW MRI is commonly used to represent the magnitude of diffusion by providing information related to cellularity and the integrity of cell membranes in tumors [8–10]. Some studies have demonstrated the value of ADC in identifying responders to NACT in breast cancer patients [7, 11, 12]. However, some other studies failed to find the association between ADC and treatment response [13–15].

Many reported DW MRI studies in tissues including breast tissues have found that for a certain range of $b$-values (degree of diffusion sensitization), the diffusion signal decay presents a non-mono-exponential behavior [8, 16–18]. Therefore, conventional ADC is insufficient to reflect the complete diffusion characteristics as it is assumed on the basis of the well-behaved mono-exponential decay. Several advanced diffusion models have been proposed to reveal the complicated water molecule diffusion behavior beyond standard ADC measurements. Bi-exponential intravoxel incoherent motion (IVIM) model utilizes low $b$-values to extract the microcapillary perfusion component from the entire DW signal, while stretched-exponential model accounts for the intravoxel water diffusion heterogeneity related with microstructural complexity at high $b$-values [16]. Although bi- and stretched-exponential models have shown potential in the diagnosis and characterization of breast cancer in previous studies [19–22], their utility in predicting treatment response to NACT has not been fully understood [23, 24].

Therefore, the purpose of this study was to determine the capability of DW MRI with mono-, bi-, and stretched-exponential models in monitoring and predicting response to NACT in breast cancer patients, and further outline a model of pCR combining DW MRI parameters, CE MRI findings, and/or clinical-pathologic variables.

Methods
Study design and patient selection
This study was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, with a waiver of the requirement to obtain patient informed consent owing to the retrospective design. Subjects were identified from a retrospective review of our medical and radiologic database from November 2015 to August 2018. One hundred seventy-two women with histologically proven invasive breast cancer who received NACT as a first line of treatment were eligible for the study. The other eligibility criteria were as follows: (i) patients were aged at least 18 years old; (ii) patients were confirmed with primary breast cancer with no distant metastasis; (iii) surgical resection was preformed after completion of NACT; and (iv) MRI including multi-$b$-value DW imaging was conducted during NACT. Of the 172 patients, 28 were excluded because (i) NACT was not completed or nonstandard treatment was used ($n=12$); (ii) tumors were less than 1 cm at pre-treatment CE MRI ($n=11$); and (iii) no pre-treatment multi-$b$-value DW MRI was available ($n=5$). Therefore, 144 patients constituted the final study population (mean age, 51.7 years; age range, 25–75 years) (Fig. 1).

**Conclusion:** Mono-exponential flow-insensitive ADC change at mid-treatment was a predictor of pCR after NACT in breast cancer.

**Keywords:** Breast cancer, Diffusion-weighted MRI, Pathologic complete response, Neoadjuvant chemotherapy, Predictive model
Neoadjuvant chemotherapy
The treatment protocols have been previously described [25]. Each patient received intravenous administration of paclitaxel at 80 mg/m² body surface area and cisplatin at 25 mg/m² body surface area for four cycles lasting 16 weeks in duration. Patients with human epidermal growth factor receptor 2 (HER2)-positive findings were allowed concomitant treatment with trastuzumab, at a loading dose of 4 mg/kg body weight, followed by a maintenance dose of 2 mg/kg. Patients underwent surgery after the completion of NACT.

MRI
Breast MRI was performed before treatment, at mid-treatment (after two cycles of NACT), and after treatment (after four cycles of NACT), prior surgery. MRI was performed by using a 3-T scanner (Ingenia; Philips Medical Systems, Best, the Netherlands) with a dedicated breast array coil. Patients were examined in the prone position. The standardized MRI protocol consisted of axial T1- and T2-weighted, sagittal fat-suppressed T2-weighted, axial fat-suppressed multi-b-value DW, and axial fat-suppressed dynamic CE MRI. DW images with spectral attenuated inversion recovery for fat suppression were acquired by using the single-shot echo planar imaging sequence with multiple b-values (0, 10, 30, 50, 100, 150, 200, 500, 800, 1000, 1500, 2000, and 2500 s/mm²). Other imaging parameters were: repetition time (TR), 4500 ms; echo time (TE), 85 ms; matrix, 108 × 128; in-plane resolution, 2.6 × 2.6 mm; section thickness, 3 mm; 16 sections; parallel acquisition with acceleration factor of two; and acquisition time, 8 min 40 s. Diffusion gradients were applied in three orthogonal directions. After DW imaging, dynamic CE MRI was performed by using the three-dimensional fat-suppressed T1-weighted gradient echo sequence before and after an intravenous bolus injection of 0.1 mmol/kg body weight of dimeglumine gadopentetate contrast agent (Magnevist; Bayer Healthcare, Berlin, Germany), with following parameters: TR, 4.7 ms; TE, 2.3 ms; flip angle, 10°; matrix, 320 × 340;
in-plane resolution, 1.0×0.9 mm; section thickness, 1 mm; four or six post-contrast dynamics; and temporal resolution, 75 s.

**Image analysis**

DW image analysis was performed by using custom software developed in MATLAB version R2019a (MathWorks, Natick, Mass, USA). Parametric maps for bi- and stretched-exponential models were generated by means of a nonlinear least squares fitting procedure at low (0, 10, 30, 50, 100, 150, 200, 500, and 800 s/mm²) and high (0, 500, 800, 1000, 1500, 2000, and 2500 s/mm²) b-values, respectively. Bi-exponential pseudodiffusion coefficient $D^*$ and perfusion fraction $f$, and stretched-exponential distributed diffusion coefficient DDC and intravoxel heterogeneity index $\alpha$ were calculated. For mono-exponential modeling, all b-value were used to fit the ADCall maps. Standard ADC maps were also calculated using two b-values. Specifically, b values of 0 and 1000 s/mm² were included to obtain the routinely used standard ADC (ADC$_{0,1000}$), and 200 and 1000 s/mm² to obtain the flow-insensitive ADC (ADC$_{200,1000}$) [21, 26].

Region of interest (ROI) delineation was performed by a radiologist with 10 years of experience in interpretation of breast MR images. ROIs encompassing the entire tumor were manually drawn on all sections of high b-value DW images. Tumor areas were defined as hyper-intensity on DW images by avoiding T2 shine-through regions (eg, cystic and necrotic components). CE MRI was used for lesion localization and boundary verification. ROIs were then transferred to corresponding parametric maps, and mean values of all voxels within the ROIs were calculated. Tumor ROIs at each treatment time point were identified by referencing the lesion location on prior MRI examinations. If no residual enhanced tumor areas appeared on post-treatment CE MRI, ROIs were placed in the same region as the last positive MRI [27].

On CE MRI, the longest diameter (size) and relative enhancement ratio (RER) of the tumor was measured. RER was defined as $\left(\frac{SI_{post} - SI_{pre}}{SI_{pre}}\right) \times 100$, where SI$_{pre}$ is the CE MRI signal intensity of the tumor before contrast injection and SI$_{post}$ is the signal intensity of the first post-contrast dynamic acquisition [28].

**Molecular biomarkers**

Statuses for estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 labeling index were determined from pre-treatment biopsy by immunohistochemistry (IHC). ER or PR positivity was defined as ≥1% nuclear immunostaining. HER2 expression was deemed as positive when membrane immunostaining was scored 3+ or 2+ with an amplification of HER2 gene demonstrated by in situ hybridization assays. Ki-67 index was assessed as the percentage of immunoreactive tumor cells, and a cutoff value of 20% was used to define the low- and high-proliferation tumor groups [29].

**Pathologic response analysis**

The final histopathologic examination was performed after surgical resection following the last cycle of NACT, and the findings were considered as the reference standard for determining the reliability of DW MRI for predicting the treatment response in our study. Patients were categorized as having a pCR if no residual invasive tumor existed in the surgical specimen with the absence of axillary lymph node invasion, regardless of the presence of ductal carcinoma in situ (DCIS).

**Statistical analysis**

Continuous variables were expressed as means ± standard deviations, and categorical variables as numbers and percentages. Clinical-pathologic characteristics were compared according to response to NACT by using the t test, $\chi^2$ test, or Fisher exact test, where appropriate. Quantitative MRI findings were initially screened for normality using the Shapiro Wilk test. Comparisons between pCR and non-pCR groups were made with independent samples t test for normally distributed variables or Wilcoxon rank sum test for non-normally distributed variables. Receiver operating characteristic (ROC) curves were generated to test the predictive ability for pCR by using the area under the ROC curve (AUC) and its 95% confidence interval (CI). Youden index was used to identify the optimal threshold.

Univariate and multivariate logistic regression analyses were performed to screen the independent clinical-pathologic and imaging predictors of pCR. Variables with a $P$ value <0.05 at univariate analysis were fed into multivariate backward stepwise logistic regression analysis. Logistic regression coefficients were exponentiated to obtain odds ratios and 95% CIs. ROC curve was constructed to calculate AUC along with its 95% CI for the predictive model. The method of DeLong et al. [30] was used for statistical comparison of AUCs between the multivariate model and univariate predictors. Leave-one-out cross-validation was applied to evaluate the performance of the predictive model, and the corresponding sensitivity, specificity and accuracy were determined. $P$ value <0.05 was considered statistically significant, except for those in which a Bonferroni correction was performed for multiple comparison. Bonferroni-adjusted significance level was set at $P$ value <0.0024 (0.05/21) for DW imaging variables (seven variables and three time points) and at $P$ value <0.0083 (0.05/6) for CE MRI variables (two variables and three time points). Statistical analyses
were carried out using SPSS version 21 (IBM SPSS Statistics, Armonk, New York, USA) and GraphPad Prism 5 (GraphPad Software, La Jolla, California, USA).

**Results**

**Patient characteristics**

Patient characteristics are listed in Table 1. Of the 144 patients, 54 (37.5%) achieved pCR at final histopathologic examination. In terms of molecular biomarkers, the pCR group showed a significant higher proportion of ER negativity (35 of 54 patients [64.8%]; \(P < 0.001\)), PR negativity (24 of 54 patients [44.4%]; \(P = 0.005\)), HER2 positivity (33 of 54 patients [61.1%]; \(P = 0.001\)), and Ki-67 ≥ 20% (52 of 54 patients [96.3%]; \(P < 0.001\)). No significant difference was observed in age (\(P = 0.876\)), menopausal status (\(P = 0.334\)), or tumor histologic type (\(P = 0.535\)) between the pCR and non-pCR groups.

**DW MRI findings**

All pre-treatment DW imaging measures showed no significant differences between patients with and those without pCR (Table 2). The time courses of diffusion-related imaging measures including \(\Delta ADC_{0,1000}\), \(\Delta ADC_{200,1000}\), \(\Delta ADC_{all}\), and DDC represented a generally increasing trend as treatment progressed, and the extent of changes during treatment differed between the pCR and non-pCR groups (Fig. 2). Examples of dynamic changes of DW imaging measures in the pCR and non-pCR groups during NACT are shown in Figs. 3 and 4. Statistical results showed that \(\Delta ADC_{0,1000}\), \(\Delta ADC_{200,1000}\), \(\Delta ADC_{all}\), and DDC were greater in patients with pCR than in patients without pCR at mid-treatment or post-treatment (\(P \leq 0.001\)). However, there were no significant differences in \(\Delta D^*\), \(\Delta f\), or \(\Delta \alpha\) between the two groups at any time point (adjusted \(P > 0.0024\)). Among the significant measures, \(\Delta ADC_{200,1000}\) at mid-treatment exhibited the highest diagnostic performance for predicting pCR, with an AUC of 0.831 (95% CI: 0.747, 0.915; \(P < 0.001\)) (Table 2).

**CE MRI findings**

Similarly, pre-treatment tumor size or RER on CE MRI did not differ significantly between patients with and those without pCR (adjusted \(P > 0.0083\)). By mid-treatment, tumor size and RER showed greater changes in patients with pCR than in patients without pCR (\(P \leq 0.001\)), with predictive AUC of 0.698 (95% CI: 0.591, 0.804; \(P = 0.001\)) and 0.706 (95% CI: 0.603, 0.809;...
P = 0.001), respectively. ΔRER at post-treatment also predictive of pCR (AUC = 0.734; 95% CI: 0.633, 0.836; P < 0.001) (Table 3).

Logistic regression modeling
Pre-treatment clinical-pathologic and mid-treatment imaging variables were used to construct a predictive model by logistic regression analysis (Table 4). Mid-treatment ΔADC_{200,1000}, ΔSize, and ΔRER were stratified into binary categorical variables using the optimal threshold of 0.33 × 10^{-3} \text{ mm}^2/\text{s}, -26.6 \text{ mm}, and -87.5\% respectively, according to the ROC curve analysis. In the univariate regression analysis, ER negativity (P < 0.001), HER2 positivity (P < 0.001), Ki-67 ≥ 20\% (P = 0.012), ΔADC_{200,1000} > 0.33 × 10^{-3} \text{ mm}^2/\text{s} (P < 0.001), ΔSize ≤ -26.6 \text{ mm} (P < 0.001), and ΔRER ≤ -87.5\% (P < 0.001) were found to be associated with a higher probability of achieving pCR. In the multivariate analysis, however, only ER negativity (odds ratio, 11.433; 95% CI: 3.363, 38.874; P < 0.001), HER2 positivity (odds ratio, 5.469; 95% CI: 1.631, 18.339; P = 0.006), and ΔADC_{200,1000} > 0.33 × 10^{-3} \text{ mm}^2/\text{s} (odds ratio, 2.847, 28.917; P < 0.001) remained significant independent factors for pCR (Table 4). The regression model combining these three variables resulted in an overall predictive performance of AUC = 0.905 (95% CI: 0.843, 0.966; P < 0.001), which was greater than the AUC of ΔADC_{200,1000} alone, with a near-significant difference (P = 0.060) (Fig. 5). By using leave-one-out cross validation, the multivariate model achieved a sensitivity of 81.1\%, a specificity of 87.5\%, and an accuracy of 85.1\% for predicting pCR.

Table 2

| Variable | Patients with pCR | Patients with non-pCR | P value* | AUC | 95% CI | P value* |
|----------|------------------|-----------------------|----------|-----|--------|----------|
| Pre-treatment | | | | | | |
| No. of patients | 54 | 90 | | | | |
| ADC_{0,1000} | 0.86 ± 0.16 | 0.85 ± 0.21 | 0.324 | 0.549 | 0.455, 0.644 | 0.324 |
| ADC_{200,1000} | 0.79 ± 0.15 | 0.77 ± 0.20 | 0.115 | 0.579 | 0.484, 0.673 | 0.115 |
| ΔD*, Δf* | 0.67 ± 0.10 | 0.67 ± 0.16 | 0.302 | 0.551 | 0.458, 0.645 | 0.302 |
| ΔADC_{200,1000} | 15.62 ± 4.18 | 15.44 ± 3.70 | 0.794 | 0.502 | 0.402, 0.601 | 0.974 |
| DDC | 9.27 ± 3.66 | 9.27 ± 2.98 | 0.729 | 0.517 | 0.417, 0.618 | 0.729 |
| Δf | 1.00 ± 0.83 | 0.98 ± 0.80 | 0.478 | 0.535 | 0.440, 0.630 | 0.478 |
| α* | 0.68 ± 0.08 | 0.67 ± 0.08 | 0.306 | 0.551 | 0.452, 0.650 | 0.306 |
| Mid-treatment | | | | | | |
| No. of patients | 37 | 64 | | | | |
| ΔADC_{0,1000} | 0.46 ± 0.26 | 0.15 ± 0.23 | <0.001 | 0.812 | 0.727, 0.897 | <0.001 |
| ΔADC_{200,1000} | 0.50 ± 0.26 | 0.19 ± 0.22 | <0.001 | 0.831 | 0.747, 0.915 | <0.001 |
| ΔADC_{all} | 0.28 ± 0.20 | 0.09 ± 0.17 | <0.001 | 0.749 | 0.640, 0.858 | <0.001 |
| ΔD*, Δf* | -3.06 ± 6.36 | -1.97 ± 6.35 | 0.409 | 0.577 | 0.460, 0.694 | 0.197 |
| ΔADC_{200,1000} | 1.78 ± 4.33 | 0.82 ± 3.86 | 0.406 | 0.550 | 0.432, 0.667 | 0.406 |
| ΔDDC | 0.78 ± 0.68 | 0.25 ± 0.35 | <0.001 | 0.778 | 0.675, 0.882 | <0.001 |
| Δf* | -0.02 ± 0.12 | -0.003 ± 0.09 | 0.478 | 0.503 | 0.364, 0.641 | 0.964 |
| Post-treatment | | | | | | |
| No. of patients | 33 | 65 | | | | |
| ΔADC_{0,1000} | 0.60 ± 0.34 | 0.30 ± 0.32 | <0.001 | 0.743 | 0.637, 0.849 | <0.001 |
| ΔADC_{200,1000} | 0.60 ± 0.32 | 0.31 ± 0.32 | <0.001 | 0.745 | 0.641, 0.849 | <0.001 |
| ΔADC_{all} | 0.35 ± 0.26 | 0.18 ± 0.22 | 0.001 | 0.693 | 0.574, 0.813 | 0.003 |
| ΔD*, Δf* | -1.84 ± 7.71 | -1.47 ± 5.90 | 0.794 | 0.528 | 0.402, 0.653 | 0.655 |
| ΔDDC | 2.90 ± 5.33 | 1.69 ± 3.73 | 0.482 | 0.544 | 0.410, 0.677 | 0.482 |
| ΔADC_{200,1000} | 0.96 ± 0.63 | 0.51 ± 0.60 | 0.001 | 0.726 | 0.610, 0.841 | <0.001 |
| Δf* | -0.05 ± 0.12 | -0.05 ± 0.10 | 0.820 | 0.503 | 0.368, 0.637 | 0.964 |

* Δf and α have no units
* P < 0.0024 (0.05/21) is defined as the Bonferroni-corrected significance level

ADC: apparent diffusion coefficient, D*: pseudodiffusion coefficient, f: perfusion fraction, DDC: distributed diffusion coefficient, α: intravoxel heterogeneity index, pCR: pathologic complete response, AUC: area under the receiver operating characteristic curve, CI: confidence interval
Identification of breast cancer patients who will benefit from NACT and achieve a final pCR is pivotal. Our study showed that mid-treatment flow-insensitive ADC changes were capable of predicting tumor treatment response. Patients with pre-treatment ER negativity and HER2 positivity, and greater mid-treatment ADC changes had more potential to achieve pCR after NACT. Advanced diffusion models including bi- and stretched-exponential models showed no additional benefit for the prediction.

Our results are concordant with those from other studies [27, 31], indicating that mid-treatment ADC changes might be predictive of pCR. Greater mid-treatment increases in tumor ADC from baseline were demonstrated in responders versus nonresponders. The increase in ADC values after NACT is believed to be a consequence of apoptosis and cell necrosis induced by chemotherapy [27]. Responders are more chemo-sensitive, thus resulting in more reduction in tumor cellularity and cell membrane integrity, reflected by greater ADC increases during treatment. Among all the ADC metrics analyzed in the study, the mono-exponential model derived ADC with $b$-values of 200 and 1000 s/mm$^2$ exhibited a superior prediction performance. According to the IVIM theory, the contribution of microcirculation-related pseudodiffusion on DW MRI signal is almost negligible at high $b$-values (e.g., $>200$ s/mm$^2$). Therefore, flow-insensitive $\text{ADC}_{200,1000}$ is merely accounted for by pure water molecule diffusion, which is thought to have a more direct association with tissue cellularity and cell membrane integrity. From another aspect, it can be implied that diffusion may outperform perfusion in predicting the treatment response of NACT in breast cancer. This implication can also be confirmed by our results.

**Discussion**

Identification of breast cancer patients who will benefit from NACT and achieve a final pCR is pivotal. Our study showed that mid-treatment flow-insensitive ADC changes were capable of predicting tumor treatment response. Patients with pre-treatment ER negativity and HER2 positivity, and greater mid-treatment ADC changes had more potential to achieve pCR after NACT. Advanced diffusion models including bi- and stretched-exponential models showed no additional benefit for the prediction.

Our results are concordant with those from other studies [27, 31], indicating that mid-treatment ADC changes might be predictive of pCR. Greater mid-treatment increases in tumor ADC from baseline were demonstrated in responders versus nonresponders. The increase in ADC values after NACT is believed to be a consequence of apoptosis and cell necrosis induced by chemotherapy [27]. Responders are more chemo-sensitive, thus resulting in more reduction in tumor cellularity and cell membrane integrity, reflected by greater ADC increases during treatment. Among all the ADC metrics analyzed in the study, the mono-exponential model derived ADC with $b$-values of 200 and 1000 s/mm$^2$ exhibited a superior prediction performance. According to the IVIM theory, the contribution of microcirculation-related pseudodiffusion on DW MRI signal is almost negligible at high $b$-values (e.g., $>200$ s/mm$^2$). Therefore, flow-insensitive $\text{ADC}_{200,1000}$ is merely accounted for by pure water molecule diffusion, which is thought to have a more direct association with tissue cellularity and cell membrane integrity. From another aspect, it can be implied that diffusion may outperform perfusion in predicting the treatment response of NACT in breast cancer. This implication can also be confirmed by our results.

![Fig. 2](image-url) Time courses of mono-, bi-, and stretched-exponential diffusion-weighted imaging measures during neoadjuvant chemotherapy. Shown are mean values from all available subjects, with error bars indicating standard deviations. A discrepancy in parameter variations was recorded between groups with and without pathologic complete response, especially for diffusion-related imaging measures including $\text{ADC}_{0,1000}$, $\text{ADC}_{200,1000}$, $\text{ADC}_{\text{all}}$, and DDC.
from bi-exponential IVIM and CE MRI analysis, showing that IVIM based pseudodiffusion coefficient $D^*$ and perfusion fraction $f$, and CE MRI based relative
Table 3  Contrast-enhanced MRI findings according to response at each time point

| Variable | Patients with pCR | Patients with non-pCR | P value | AUC | 95% CI | P value |
|----------|------------------|-----------------------|---------|-----|--------|---------|
| Pre-treatment         |                  |                       |         |     |        |         |
| No. of patients         | 54               | 90                     |         |     |        |         |
| Size (mm)             | 39.8 ± 21.2      | 44.3 ± 18.8            | 0.189   | 0.578 | 0.475, 0.681 | 0.119   |
| RER (%)               | 164.1 ± 66.5     | 152.6 ± 57.0           | 0.271   | 0.551 | 0.452, 0.650 | 0.305   |
| Mid-treatment          |                  |                       |         |     |        |         |
| No. of patients         | 37               | 64                     |         |     |        |         |
| ΔSize (mm)            | −27.4 ± 16.6     | −17.1 ± 14.2           | 0.001   | 0.698 | 0.591, 0.804 | 0.001   |
| ΔRER (%)              | −101.2 ± 81.1    | −36.8 ± 81.1           | <0.001  | 0.706 | 0.603, 0.809 | 0.001   |
| Post-treatment         |                  |                       |         |     |        |         |
| No. of patients         | 33               | 65                     |         |     |        |         |
| ΔSize (mm)            | −34.0 ± 18.9     | −24.6 ± 18.5           | 0.021   | 0.661 | 0.549, 0.774 | 0.009   |
| ΔRER (%)              | −135.1 ± 81.4    | −60.5 ± 79.8           | <0.001  | 0.734 | 0.633, 0.836 | <0.001  |

* P < 0.0083 (0.05/6) is defined as the Bonferroni-corrected significance level

RER: relative enhancement ratio; pCR: pathologic complete response; AUC: area under the receiver operating characteristic curve; CI: confidence interval

Table 4  Univariate and multivariate analyses of variables associated with pCR

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|----------------------|
|                                 | Odds ratio*         | P value              |
|                                 |                     |                      |
| Pre-treatment                   |                     |                      |
| Age                             | 0.986 (0.953, 1.021)| 0.429                |
| Menopause (post- vs. pre-menopausal) | 2.083 (0.895, 4.850) | 0.089                |
| Histologic type (IDC vs. Non-IDC) | 1.770 (0.177, 17.665) | 0.626                |
| ER (negative vs. positive)      | 11.388 (4.367, 29.698) | <0.001               |
| PR (negative vs. positive)      | 2.388 (0.970, 5.881) | 0.058                |
| HER2 (positive vs. negative)    | 5.104 (2.131, 12.227) | <0.001               |
| Ki-67 (≥ 20% vs. < 20%)         | 14.087 (1.795, 110.566) | 0.012               |
| Mid-treatment                   |                     |                      |
| ΔADC_{200,1000} (> 0.33 vs. ≤ 0.33 × 10^{-3} mm^2/s) | 13.481 (5.066, 35.877) | <0.001              |
| ΔSize (≤ 26.6 vs. > − 26.6 mm)  | 5.098 (2.070, 12.553) | <0.001               |
| ΔRER (≤ − 87.5% vs. > − 87.5%) | 4.202 (1.748, 10.100) | 0.001               |

* Data in parentheses are 95% confidence intervals

For binary categorical variables, the latter category in the parentheses was used as the reference

IDC: invasive ductal carcinoma; pCR: pathologic complete response; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; ADC: apparent diffusion coefficient; RER: relative enhancement ratio

enhancement ratio RER were all inferior to ADC metrics for the prediction.

Like previous studies [12, 13, 27, 32], pre-treatment ADC values were not predictive of NACT response in our cohort. This accordance can partly be attributed to the same type of reference standard used in these studies and ours, that is, responders and nonresponders were categorized by means of final histopathologic assessment. In the studies of Santamaria et al. [12] and Woodhams et al. [13], pCR was defined as the complete absence of any residual invasive cancer or DCIS, while in the studies of Partridge et al. [27], Fangberget et al. [32], and ours, pCR was defined as the complete absence of invasive cancer of any size, regardless of DCIS. Though the definition of pCR is slightly different among these studies, all reported ADC values prior to therapy did not predict pCR. Some other studies used clinical response (tumor size shrinkage on radiologic examination) as the reference standard and conflicting results have been demonstrated [33, 34]. For example, Park et al. [33] and Sharma et al. [34] showed that pre-treatment ADC values had predictive value of clinical therapeutic response, with clinical responders representing substantially lower pretreatment ADC values compared with nonresponders.
Predictive value of bi- and stretched-exponential DW MRI in assessing treatment response of NACT in breast cancer is rarely investigated. The results of this study demonstrated no significant benefit of bi-exponential ($D^*$, $f$) and stretched-exponential ($\alpha$) parameters for predicting pCR as compared with mono-exponential ADC. Changes of bi-exponential ($D^*$, $f$) and stretched-exponential ($\alpha$) parameters during NACT were not significantly different between responders and non-responders, concordant with the results of prior studies of Bedair et al. [23] and Kim et al. [35]. The limited value of bi-exponential ($D^*$, $f$) may be explained by their high estimation uncertainty due to the non-linearity of the bi-exponential model [35, 36]. Though stretched-exponential $\alpha$ is proposed to be a heterogeneity index of water diffusion environment, its underlying biologic basis still remains unclear. Likewise, in a recent study on response assessment of liver metastases to chemotherapy in colorectal cancer, the usefulness of $\alpha$ value was also not identified [37].

In clinical settings, treatment response is mostly evaluated using tumor size alteration according to the RECIST criteria. However, our results showed that tumor size measured on CE MRI was less useful than ADC for predicting treatment response to NACT. This finding is consistent with that of a previous study showing that ADC change after the first cycle of NACT in breast cancer was statistically significant compared with volume and diameter, even though clinical response criteria were used as the reference standard in the study. Breast CE MRI provides an additional tool for assessment of tumor size. However, therapy-induced changes may cause substantial over- or under-estimation of tumor size, especially in well-responding tumors [38]. Therefore, tumor shrinkage on CE MRI may be not an exact reflection of the true histologic regression status. In addition, it is also believed that morphologic changes often occur relatively late and thus may not accurately assess early tumor response during the time course of NACT [7, 31].

In this study, breast cancer with ER/PR negativity, HER2 positivity or Ki-67 $\geq$ 20% was more likely to reach a pCR after NACT. This finding has already been recognized [39, 40] and probably a higher cellular proliferation of these tumor types renders tumor cells more sensitive to chemotherapy. Multivariate logistic regression analysis suggested that ER negativity, HER2 positivity and mid-treatment $\Delta$ADC$_{200,1000} > 0.33 \times 10^{-3}$ mm$^2$/s were the significant predictors. ROC analysis indicated a better predicting performance when all the three variables were included in the model, with an AUC of 0.905. This is in agreement with the results published by Santamaría et al. [12], who found the model incorporating breast cancer subtype and MRI features (including ADC ratio after treatment) demonstrated a higher accuracy relative to prediction of pCR with an AUC of 0.92.

Our study had limitations. First, this was a retrospective study in a single institution. Patient selection bias may exist. Second, due to the retrospective design, MRI was not performed during early treatment, so an evaluation of the early response to NACT was not possible. The role of $\Delta$ADC in prediction of pCR at early treatment, however, remains controversial in the literature [7, 27]. Third, the interobserver variability or reproducibility of quantitative DW MRI measurements was not evaluated. However, we calculated the tumor DW MRI parameters over the entire tumor volume delineated by one experienced in breast MRI. In addition, the interobserver agreement of mono-, bi-, and stretched-exponential DW MRI parameters has been demonstrated to be good to excellent in our previous studies [20, 41]. Fourth, quantitative DW MRI parameters were measured by averaging all voxels within the ROI. More comprehensive analytic methods may provide added-value information. For example, histogram and texture analyses highlight the different heterogeneous appearances of breast cancer on ADC maps, which have proved to be related with tumor biology [42, 43].
Conclusions
In conclusion, mono-exponential flow-insensitive ADC change at mid-treatment was the most accurate predictor of pCR to neoadjuvant chemotherapy in patients with breast cancer among all parameters from mono-, bi-, and stretched-exponential DW MRI models. Patients with pre-treatment ER negativity and HER2 positivity, and greater mid-treatment ADC changes are more likely to completely respond to neoadjuvant chemotherapy. If these results are validated in future studies with larger cohort in more institutions, it could help guide the treatment and predict the long-term outcome.

Abbreviations
DW: Diffusion-weighted; pCR: Pathologic complete response; NACT: Neoadjuvant chemotherapy; ADC: Apparent diffusion coefficient; CE: Contrast-enhanced; IVIM: Intravoxel incoherent motion; HER2: Human epidermal growth factor receptor 2; TR: Repetition time; TE: Echo time; fD: Pseudodiffusion coefficient; f: Perfusion fraction; DDC: Distributed diffusion coefficient; α: Intravoxel heterogeneity index; ROI: Region of interest; RER: Relative enhancement ratio; ER: Estrogen receptor; PR: Progesterone receptor; IHC: Immunohistochemistry; DCIS: Ductal carcinoma in situ; ROC: Receiver operating characteristic; AUC: Area under the receiver operating characteristic curve; CI: Confidence interval.

Acknowledgements
Not applicable.

Authors’ contributions
SS, JC, and JH designed the study, SS, YY, XG, DZ, and FC collected the data, SS, YY, XG, and MC analyzed the data, SS provided statistical analysis, SS, YY, XG, and MC revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant Numbers 81771642, 81501458); the Clinical Research Plan of Shanghai Shen Kang Hospital Development Center (Grant Number SHDC2020CR0068); the Medical Engineering Cross Research Foundation of Shanghai Jiao Tong University (Grant Number YG2014ZD05); and the Shanghai "Rising Stars of Medical Talent" Youth Development Program (Youth Medical Talents—Medical Imaging Practitioner Program SHWRS(2020)_087).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, with a waiver of the requirement to obtain patient informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Rd, Shanghai 200127, China. 2 Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.

References
1. Kaufmann M, von Minckwitz G, Bear HD, Budzatz A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.
2. Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, D’Giovanna MP, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121:2544–52.
3. Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.
4. Londero V, Bazzocchi M, Del Frate C, Pugliesi F, Di Loreto C, Francescatti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371–9.
5. Hylton NM, Blume JD, Bernreuter WK, Pissano ED, Rosen MA, Morris EA, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657A-SPY TRIAL. Radiology. 2012;263:663–72.
6. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843–7.
7. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009;22:104–13.
8. Le Bihan D. Apparent diffusion coefficient and beyond: what diffusion MR imaging can tell us about tissue structure. Radiology. 2013;268:318–22.
9. Padhani AR, Liu G, Koh DM, Chenetvert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.
10. Zhuang Z, Zhang Q, Zhang D, Cheng F, Suo S, Geng X, et al. Utility of apparent diffusion coefficient as an imaging biomarker for assessing the proliferative potential of invasive ductal breast cancer. Clin Radiol. 2018;73:473–8.
11. Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, et al. Multimparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Invest Radiol. 2015;50:195–204.
12. Santamaria G, Bargallo X, Fernandez PL, Farrus B, Caparros X, Velasco M. Neoadjuvant systemic therapy in breast cancer: Association of contrast-enhanced MR imaging findings, diffusion-weighted imaging findings, and tumor subtype with tumor response. Radiolology. 2017;283:663–72.
13. Woodhams R, Rakuta S, Hata H, Hivabuchi K, Kuranami M, Gautam S, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging—comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010;254:357–66.
14. Buš E, Belli P, Costantini M, Cipriani A, Di Matteo M, Bonatessa A, et al. Role of the apparent diffusion coefficient in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Breast Cancer. 2015;15:370–80.
15. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol. 2010;49:354–60.
16. Ima M, Le Bihan D. Clinical intravoxel incoherent motion and diffusion MR imaging: past, present, and future. Radiology. 2016;278:13–32.
17. Rosenkranz AB, Padhani AR, Chenetvert TL, Koh DM, De Keyser F, Taouli B, et al. Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. J Magn Reson Imaging. 2015;42:1190–20.
18. Suo S, Cao M, Zhu W, Li L, Li J, Shen F, et al. Stroke assessment with intravoxel incoherent motion diffusion-weighted MRI. NMR Biomed. 2016;29:320–8.

19. Sigmund EE, Cho GY, Kim S, Finn M, Moccaldi M, Jensen JH, et al. Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer. Magn Reson Med. 2011;65:1437–47.

20. Suo S, Che S, Zhao X, Ou Y, Li J, Wang M, Wu B, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer. Medicine. 2016;95:e2420.

21. Xu Y, Wang Y, Yuan C, Sheng X, Sha R, Dai H, et al. Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy. Ther Adv Med Oncol. 2020;12:1758835920940886.

22. You C, Li J, Zhi W, Chen Y, Yang W, Gu Y, et al. The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI association with prognostic factors in HER2-positive breast cancer. J Transl Med. 2019;17:182.

23. Bedair R, Priest AJ, Patterson AJ, McLean MA, Graves MJ, Manavaki R, et al. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations. Eur Radiol. 2017;27:2726–36.

24. Che S, Zhao X, Ou Y, Li J, Wang M, Wu B, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer. Medicine. 2016;95:e2420.

25. Turner JR, Goa PE, Sjobakk TE, Ostlie A, Fjosne HE, Bathen TF. A simplified approach to measure the effect of the microvasculature in diffusion-weighted MRI applied to breast tumors: preliminary results. Radiology. 2016;281:73–81.

26. Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018;287:432–41.

27. Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018;287:432–41.

28. Suo S, Lin N, Wang H, Zhang L, Wang R, Zhang S, et al. Intravoxel incoherent motion and quantitative non-Gaussian diffusion MR imaging: evaluation of the diagnostic and prognostic value of several markers of malignant and benign breast lesions. Radiology. 2018;287:432–41.

29. You C, Li J, Zhi W, Chen Y, Yang W, Gu Y, et al. The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI association with prognostic factors in HER2-positive breast cancer. J Transl Med. 2019;17:182.

30. Iima M, Kataoka M, Kanao S, Onishi N, Kawai M, Ohashi A, et al. Intravoxel incoherent motion diffusion-weighted MRI. NMR Biomed. 2016;29:320–8.

31. Bullard EE, Cho GY, Kim S, Finn M, Moccaldi M, Jensen JH, et al. Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer. Magn Reson Med. 2011;65:1437–47.

32. Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebretsen O, Naume B, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MRI imaging. Eur Radiol. 2011;21:1188–99.

33. Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010;257:56–63.

34. Sharma U, Agarwal K, Sah RG, Parshad R, Seenu V, Mathur S, et al. Can multi-parametric MRI based approach improve the predictive value of pathological and clinical therapeutic response in breast cancer patients? Front Oncol. 2018;8:319.

35. Kim Y, Kim SH, Lee HW, Song BJ, Kang BJ, Lee A, et al. Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Magn Reson Imaging. 2018;48:27–33.

36. Nougaert S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, et al. Intravoxel incoherent motion-derived histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses. Radiology. 2016;280:446–54.

37. Zhou Y, Zhang HX, Zhang XS, Sun YF, Ye KB, Sang XQ, et al. Non-mono-exponential diffusion models for assessing early response of liver metastases to chemotherapy in colorectal cancer. Cancer Imaging. 2019;19:39.

38. Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Ludemann HP, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13:1213–23.

39. Faneyte IF, Schrama JG, Petersen JL, Remijansen PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88:406–12.

40. Li XB, Krishnamurti U, Bhattachar S, Klimov S, Reid MD, O’Regan R, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145:871–8.

41. Suo S, Zhang K, Cao M, Suo X, Hua J, Geng X, et al. Characterization of breast masses as benign or malignant at 3.0T MRI with whole-lesion multi-parametric MR based approach improve the predictive value of the apparent diffusion coefficient. J Magn Reson Imaging. 2016;43:894–902.

42. Suo S, Zhang D, Cheng F, Cao M, Hua J, Lu J, et al. Added value of mean and entropy of apparent diffusion coefficient values for evaluating histologic phenotypes of invasive ductal breast cancer with MR imaging. Eur Radiol. 2019;29:1425–34.

43. Leithner D, Bernard-Davila B, Martinez DF, Horvat JV, Jochelson MS, Naume B, et al. Neoadjuvant chemotherapy in breast cancer—response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MRI imaging. Eur Radiol. 2011;21:1188–99.